Profile data is unavailable for this security.
About the company
GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). Its product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. The Company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) or lupus and multiple sclerosis (MS).
- Revenue in USD (TTM)0.00
- Net income in USD-12.77m
- Incorporated2018
- Employees4.00
- LocationGRI Bio Inc2223 Avenida De La Playa, Suite 208LA JOLLA 92037United StatesUSA
- Phone+1 (619) 400-1171
- Fax+1 (302) 655-5049
- Websitehttps://www.gribio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neubase Therapeutics Inc | 0.00 | -13.73m | 1.42m | 37.00 | -- | 0.1543 | -- | -- | -7.78 | -7.78 | 0.00 | 2.45 | 0.00 | -- | -- | -- | -53.51 | -- | -64.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Agentix Corp | 0.00 | -1.01m | 1.42m | -- | -- | -- | -- | -- | -0.0253 | -0.0253 | 0.00 | -0.071 | 0.00 | -- | -- | -- | -907.08 | -- | -- | -- | -- | -- | -- | -- | -- | -96.41 | -- | -- | -- | -- | -- | -- | -- | -- |
| Drazcanna Inc | 2.05m | -5.71m | 1.47m | -- | -- | -- | -- | 0.7192 | -0.7024 | -0.7024 | 0.2492 | 0.1004 | 0.685 | -- | 23.88 | -- | -191.19 | -- | -643.20 | -- | -11.20 | -- | -279.10 | -- | -- | -33.04 | 0.2445 | -- | -- | -- | -- | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -19.94m | 1.49m | 4.00 | -- | -- | -- | -- | -64.01 | -64.01 | 0.00 | -0.2389 | 0.00 | -- | -- | 0.00 | -160.06 | -42.39 | -280.99 | -56.41 | -- | -- | -- | -- | -- | -- | 1.14 | -- | -- | -- | 48.52 | -- | -- | -- |
| CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 1.54m | 0.00 | -- | 0.8665 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
| GRI Bio Inc | 0.00 | -12.77m | 1.59m | 4.00 | -- | 0.4798 | -- | -- | -26.90 | -26.90 | 0.00 | 0.8753 | 0.00 | -- | -- | 0.00 | -382.23 | -192.93 | -869.57 | -353.99 | -- | -- | -- | -37,650.49 | -- | -16.80 | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |
| SOHM Inc | -100.00bn | -100.00bn | 1.60m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Mallinckrodt PLC | 1.91bn | -1.49bn | 1.60m | 2.80k | -- | -- | -- | 0.0008 | -161.65 | -161.63 | 89.63 | 55.44 | 0.4062 | 1.57 | 4.94 | 681,821.40 | -31.61 | -12.49 | -36.10 | -15.85 | 26.22 | 35.68 | -77.83 | -44.38 | 1.63 | -0.3456 | 0.6164 | -- | -2.53 | -10.31 | -83.00 | -- | -- | -- |
| Cannabis Suisse Corp | 30.00k | -254.75k | 1.62m | -- | -- | -- | -- | 54.07 | -0.0057 | -0.0057 | 0.0007 | -0.0103 | 0.0675 | -- | -- | -- | -57.35 | -149.71 | -238.71 | -- | 8.37 | -39.11 | -849.17 | -427.20 | -- | -13.57 | 3.38 | -- | 28.70 | 9.00 | -87.10 | -- | -- | -- |
| Stemcell Holdings Inc | 9.98m | 3.10m | 1.64m | -- | -- | -- | 0.5008 | 0.1645 | 0.00008 | 0.00008 | 0.0003 | 0.0002 | 1.12 | -- | 5.20 | -- | 34.90 | -- | 68.19 | -- | 77.19 | -- | 31.04 | -- | -- | -- | 0.00 | -- | 85.10 | -- | 71.82 | -- | -- | -- |
| LadRx Corp | 0.00 | 331.63k | 1.67m | 2.00 | 5.75 | 15.53 | 4.85 | -- | 0.5857 | 0.5857 | 0.00 | 0.2168 | 0.00 | -- | -- | 0.00 | 17.58 | -58.97 | 480.72 | -78.44 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 106.96 | -- | -- | -- |
| Bluejay Diagnostics Inc | 0.00 | -7.41m | 1.68m | 10.00 | -- | -- | -- | -- | -6.69 | -6.69 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -92.89 | -- | -113.91 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -7.07 | -- | -- | -- |
| Procyon Corp | 4.70m | -314.48k | 1.69m | 17.00 | -- | 0.7597 | -- | 0.3597 | -0.0388 | -0.0388 | 0.5804 | 0.2901 | 1.40 | 1.95 | 8.58 | 276,481.20 | -8.90 | 3.52 | -10.60 | 4.23 | 77.60 | 73.30 | -6.35 | 2.52 | 2.70 | -- | 0.00 | -- | -3.22 | 3.11 | 70.44 | -- | 30.98 | -- |
| InVitro International | 716.89k | 6.22k | 1.70m | 16.00 | 214.00 | 2.33 | -- | 2.38 | 0.0004 | 0.0004 | 0.0402 | 0.0321 | 1.15 | -- | -- | -- | 0.995 | 7.89 | 1.09 | 8.83 | -- | -- | 0.8676 | 5.90 | -- | -- | -- | -- | -5.11 | 1.33 | -87.77 | -16.14 | -- | -- |
| American Green Inc | -100.00bn | -100.00bn | 1.71m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to GRI Bio Inc's reporting currency: US Dollar USD
6.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Altium Capital Management LPas of 31 Mar 2024 | 187.98k | 4.98% |
| HRT Financial LLCas of 31 Mar 2024 | 19.51k | 0.52% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 12.70k | 0.34% |
| UBS Securities LLCas of 31 Mar 2024 | 8.02k | 0.21% |
| Tower Research Capital LLCas of 31 Mar 2024 | 6.03k | 0.16% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 4.00 | 0.00% |
| Geode Capital Management LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 0.00 | 0.00% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Citadel Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
